Plain-English translation of NCT05868174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination approach for treating advanced solid tumors that have a specific protein marker called CAIX. The study combines 177Lu-TLX250—a radioactive antibody designed to target tumors with this protein—with peposertib, an oral medication taken by mouth. The goal is to see whether this combination can shrink tumors and help patients live longer.
Many patients with advanced cancers stop responding to standard treatments or aren't eligible for them, leaving limited options. This medication is being tested to provide a new treatment approach that might work differently than standard therapies and could help patients whose tumors have this specific protein marker.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would first receive a diagnostic imaging injection to confirm your tumor expresses the target protein. Then you would receive injections of the radioactive medication on day 1 of each 84-day cycle, and take the oral pill twice daily for 18 days of each cycle. You would continue for 3 cycles (about 6 months) or until your tumor progresses significantly or side effects become too severe, with regular blood tests and imaging scans to monitor your response.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Australia